-+ 0.00%
-+ 0.00%
-+ 0.00%

Elicio says Phase 2 AMPLIFY-7P trial of ELI-002 7P misses primary DFS endpoint in adjuvant pancreatic cancer

PUBT·06/15/2026 11:00:23
Listen to the news
Elicio says Phase 2 AMPLIFY-7P trial of ELI-002 7P misses primary DFS endpoint in adjuvant pancreatic cancer
  • Elicio Therapeutics reported Phase 2 AMPLIFY-7P results for ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer; results were presented today.
  • The study missed its main disease-free survival goal in the overall population, weighing on the near-term registrational path.
  • Post-hoc analyses indicated a clearer benefit in patients with complete tumor removal, supporting a narrower target population for late-stage development.
  • Immune-response findings aligned with better clinical outcomes, reinforcing the drug’s biological activity despite the primary endpoint miss.
  • Planning shifted to a Phase 3 program focused on completely resected patients with longer dosing; execution depends on financing or partnering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150700PRIMZONEFULLFEED9746752) on June 15, 2026, and is solely responsible for the information contained therein.